Trial Profile
A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 10 Apr 2023 ). Final survival analyses and updated results , published in the Journal of Clinical Oncology
- 12 Oct 2017 Results of pooled data from two phase 3 trial ( A6181034 and Axis trial ) assessing important group differences on the functional assessment of cancer therapy-kidney symptom index disease-related symptoms in patients with metastatic renal cell carcinoma, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 06 Jun 2017 Results (n=373) of retrospective analysis of this study to provide outcomes benchmarks for current and future clinical trials interpretation presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.